(3-bromoimidazo[1,2-a]pyridin-6-yl)methanol 在
二氧化锰 作用下,
以
氯仿 为溶剂,
反应 2.0h,
以to give 242 mg (81%) of 3-bromoimidazo[1,2-a]pyridine-6-carbaldehyde as a white solid的产率得到3-溴咪唑并[1,2-a]吡啶-6-甲醛
参考文献:
名称:
THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS
The present invention provides compounds, compositions thereof, and methods of using the same.
本发明提供了化合物、其组合物以及使用方法。
[EN] THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIOZOLIDINEDIONE UTILISÉS EN TANT QU'INHIBITEURS DE LA P13-KINASE
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2008014219A8
公开(公告)日:2009-03-12
GCN2 INHIBITORS AND USES THEREOF
申请人:Merck Patent GmbH
公开号:EP3746071A1
公开(公告)日:2020-12-09
[EN] GCN2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GCN2 ET LEURS UTILISATIONS
申请人:MERCK PATENT GMBH
公开号:WO2019148136A1
公开(公告)日:2019-08-01
The present invention provides compounds, compositions thereof, and methods of using the same. Compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of GCN2 kinase.
THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS
申请人:Adams Nicholas D.
公开号:US20090215818A1
公开(公告)日:2009-08-27
Invented is a method of inhibiting the activity/function of PI3 kinases using thiozolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiozolidinedione derivatives.